14-02-2023, 13:16

Basilea reports strong financial results 2022 based on

22% year-on-year increase of royalty income from antifungal Cresemba®Operating profit of CHF 18.5 million and net
Globe Newswire14-02-2023, 13:16
7-02-2023, 13:33

Continued strong Cresemba® (isavuconazole) sales

Basel/Allschwil, Switzerland, February 07, 2023 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage
Globe Newswire7-02-2023, 13:33